blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3472160

EP3472160 - BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.12.2021
Database last updated on 14.06.2024
FormerThe patent has been granted
Status updated on  22.01.2021
FormerGrant of patent is intended
Status updated on  30.09.2020
FormerRequest for examination was made
Status updated on  14.08.2020
FormerGrant of patent is intended
Status updated on  27.01.2020
FormerRequest for examination was made
Status updated on  22.03.2019
FormerThe international publication has been made
Status updated on  28.12.2017
Formerunknown
Status updated on  05.07.2017
Most recent event   Tooltip23.06.2023Lapse of the patent in a contracting state
New state(s): CY		published on 26.07.2023  [2023/30]
Applicant(s)For all designated states
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse / BE
[2021/07]
Former [2019/17]For all designated states
Janssen Pharmaceutica, N.V.
Turnhoutseweg 30
2340 Beerse / BE
Inventor(s)01 / BERTHELOT, Didier, Jean-Claude
Janssen-Cilag
1 Rue Camille Desmoulins
TSA 91003
92787 Issy-les Moulineaux Cedex 9 / FR
02 / MEVELLEC, Laurence, Anne
Janssen-Cilag
1 Rue Camille Desmoulins
TSA 91003
92787 Issy-les Moulineaux Cedex 9 / FR
03 / ANGIBAUD, Patrick, René
Janssen-Cilag
1 Rue Camille Desmoulins
TSA 91003
92787 Issy-les Moulineaux Cedex 9 / FR
04 / COUPA, Sophie
Janssen-Cilag
1 Rue Camille Desmoulins
TSA 91003
92787 Issy-les Moulineaux Cedex 9 / FR
05 / DEMESTRE, Christophe, Gabriel, Marcel
Janssen-Cilag
1 Rue Camille Desmoulins
TSA 91003
92787 Issy-les Moulineaux Cedex 9 / FR
06 / MEERPOEL, Lieven
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse / BE
07 / MERCEY, Guillaume, Jean, Maurice
Janssen-Cilag
1 Rue Camille Desmoulins
TSA 91003
92787 Issy-les Moulineaux Cedex 9 / FR
08 / MEYER, Christophe
Janssen-Cilag
1 Rue Camille Desmoulins
TSA 91003
92787 Issy-les Moulineaux Cedex 9 / FR
09 / PASQUIER, Elisabeth, Thérèse, Jeanne
Janssen-Cilag
1 Rue Camille Desmoulins
TSA 91003
92787 Issy-les Moulineaux Cedex 9 / FR
10 / PILATTE, Isabelle, Noëlle, Constance
Janssen-Cilag
1 Rue Camille Desmoulins
TSA 91003
92787 Issy-les Moulineaux Cedex 9 / FR
11 / PONCELET, Virginie, Sophie
Janssen-Cilag
1 Rue Camille Desmoulins
TSA 91003
92787 Issy-les Moulineaux Cedex 9 / FR
12 / QUEROLLE, Olivier, Alexis, Georges
Janssen-Cilag
1 Rue Camille Desmoulins
TSA 91003
92787 Issy-les Moulineaux Cedex 9 / FR
 [2019/17]
Representative(s)Lenaerts, Philip
Johnson & Johnson Patent Law Department
Turnhoutseweg 30
2340 Beerse / BE
[2019/17]
Application number, filing date17732059.515.06.2017
[2019/17]
WO2017EP64671
Priority number, dateEP2016017471516.06.2016         Original published format: EP 16174715
[2019/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017216292
Date:21.12.2017
Language:EN
[2017/51]
Type: A1 Application with search report 
No.:EP3472160
Date:24.04.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 21.12.2017 takes the place of the publication of the European patent application.
[2019/17]
Type: B1 Patent specification 
No.:EP3472160
Date:24.02.2021
Language:EN
[2021/08]
Search report(s)International search report - published on:EP21.12.2017
ClassificationIPC:C07D471/04, C07D487/04, A61K31/496, A61P35/00
[2019/17]
CPC:
C07D487/04 (EP,EA,KR,US); C07D471/04 (EP,EA,KR,US); A61K31/496 (KR);
A61P35/00 (EP,KR,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/17]
Extension statesBA16.01.2019
ME16.01.2019
Validation statesMA16.01.2019
MD16.01.2019
TitleGerman:BICYCLISCHE PYRIDIN-, PYRAZIN- UND PYRIMIDINDERIVATE ALS PI3K-BETA-HEMMER[2019/17]
English:BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS[2019/17]
French:PYRIDINE BICYCLIQUE, PYRAZINE ET DÉRIVÉS DE PYRIMIDINE UTILISÉS COMME INHIBITEURS DE PI3K BETA[2020/04]
Former [2019/17]DÉRIVÉS BICYCLIQUES DE PYRIDINE, DE PYRAZINE ET DE PYRIMIDINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K BÊTA
Entry into regional phase16.01.2019National basic fee paid 
16.01.2019Designation fee(s) paid 
16.01.2019Examination fee paid 
Examination procedure16.01.2019Examination requested  [2019/17]
16.01.2019Date on which the examining division has become responsible
28.01.2020Communication of intention to grant the patent
08.06.2020Fee for grant paid
08.06.2020Fee for publishing/printing paid
15.07.2020Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
14.08.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
01.10.2020Communication of intention to grant the patent
08.01.2021Receipt of the translation of the claim(s)
Opposition(s)25.11.2021No opposition filed within time limit [2022/05]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
14.08.2020Request for further processing filed
14.08.2020Full payment received (date of receipt of payment)
Request granted
26.08.2020Decision despatched
Fees paidRenewal fee
01.07.2019Renewal fee patent year 03
30.06.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT24.02.2021
CY24.02.2021
CZ24.02.2021
EE24.02.2021
PL24.02.2021
RO24.02.2021
RS24.02.2021
SK24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
PT24.06.2021
[2023/30]
Former [2021/50]AT24.02.2021
CZ24.02.2021
EE24.02.2021
PL24.02.2021
RO24.02.2021
RS24.02.2021
SK24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
PT24.06.2021
Former [2021/48]AT24.02.2021
CZ24.02.2021
EE24.02.2021
PL24.02.2021
RS24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
PT24.06.2021
Former [2021/46]AT24.02.2021
PL24.02.2021
RS24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
PT24.06.2021
Former [2021/39]PL24.02.2021
RS24.02.2021
BG24.05.2021
GR25.05.2021
PT24.06.2021
Former [2021/37]RS24.02.2021
BG24.05.2021
GR25.05.2021
PT24.06.2021
Former [2021/36]BG24.05.2021
GR25.05.2021
PT24.06.2021
Former [2021/33]PT24.06.2021
Cited inInternational search[AD]WO2011110545  (JANSSEN PHARMACEUTICA NV [BE], et al) [AD] 1-15 * page 1, line 6 - page 1, line 13; claim - *;
 [AD]WO2013095761  (GLAXOSMITHKLINE LLC [US], et al) [AD] 1-15 * page 1, line 5 - page 1, line 10; claim - *;
 [A]WO2014009296  (UCB PHARMA SA [BE]) [A] 1-15* page 1, line 4 - page 2, line 23; claims 1-3 *
by applicantWO2007103756
 WO2008014219
 WO2009021083
 WO2009088990
 WO2010089292
 WO2011022439
 WO2011041399
 WO2011110545
 WO2011123751
 WO2012047538
 WO2012116237
 WO2013028263
 US2013157977
 WO2013095761
    - K.D COURTNEY; R.B. CORCORAN; J.A. ENGELMAN, Journal of Clinical Oncology., (20100000), vol. 28, page 1075
    - B. VANHAESEBROECK; M.D. WATERFIELD, Experimental Cell Research., (19990000), vol. 253, pages 239 - 254
    - ZHAO L.; VOGT P. K, Oncogene, (20080000), vol. 27, pages 5486 - 5496
    - MYERS M. P. et al, Proc. Natl. Acad. Sci. U.S.A., (19980000), vol. 95, pages 13513 - 13518
    - STOKOE D. et al, Science, (19970000), vol. 277, pages 567 - 570
    - D. R. CALNAN; A. BRUNET, Oncogene, (20080000), vol. 27, page 2276
    - JIA S. et al, Nature, (20080000), vol. 454, pages 776 - 779
    - WEE S. et al, Proc. Natl. Acad. Sci (USA), (20080000), vol. 105, page 13057
    - S. P. JACKSON et al., Nature Medicine., (20050000), vol. 11, pages 507 - 514
    - MARQUES RB et al., "High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models", Eur Urol, vol. 67, no. 6, (20140600), pages 1177 - 1185, URL: http://dx.doi.org/10.1016/j.eururo.2014.08.053
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.